TissueNetix, Inc. Elects Board of Directors

Robert Ellis Elected Chairman of the Board

San Diego, California, June 8, 2012 – TissueNetix, Inc. today announced the forming of a board of directors and the election of the members of this board. Robert Ellis was elected to the position of Chairman of the Board.  The other members of the Board are Dr. David A. Giegel, President and CSO of TissueNetix, Sandra K. Hara, CPA, owner of Hara CPA Professional Services and part-time CFO for TissueNetix and Dr. Can (“Jon”) Özbal, Director, RapidFire Operations, Agilent Technologies.

 "I am very please to have Ms. Sandra Hara and Dr Can Ozbal on our board of Directors.  Ms. Hara brings strong financials skills and experience with helping growing companies manage their finances and taxes.  Dr. Ozbal brings both start up experience and experience in developing products to address the needs of the pharmaceutical market,” said Robert Ellis.

Sandra Hara brings the highest level of experience to the TissueNetix board. That experience includes more than fifteen years in public accounting and tax, and another fifteen years in the private sector working with a wide range of companies from start-ups to companies with revenues of $500 Million. She has held positions of Controller, CFO and COO, giving her the wide range of knowledge to understand every business’ needs.

Sandra’s 30-year career in accounting and finance includes expertise in creating accounting policies and procedures as well as providing direction in all phases of accounting department management and operations. In addition, she has worked closely with a variety of industries including retail, construction, high-tech, entertainment, legal, restaurant, telecommunications, manufacturing and non-profit organizations. 

Can has 20 years of experience in designing, manufacturing, and commercializing bioanalytical instruments and workflows to help solve challenging problems in a wide range of life science and drug discovery applications.  In 2000, Can joined BioTrove Inc. as one of the first employees where he helped to develop and commercialize a high-throughput mass spectrometry based technology, eventually serving as the Vice President and General Manager of the RapidFire Business Unit of the company.  Upon the acquisition of BioTrove by Life Technologies in 2009, Can was involved in spinning out the RapidFire business as an independent company called Biocius Life Sciences where he served as Chief Operating Officer.  Biocius was acquired by Agilent Technologies in 2011 where Can is currently the Director of the RapidFire business and manager of the Wakefield, MA site of the company.

Can and his colleagues successfully built RapidFire into a profitable business with global operations.  All of the top 15 global pharmaceutical companies along with numerous smaller pharmaceutical and biotechnology companies are current users of RapidFire technology.  Originally developed as a high-throughput screening tool, RapidFire is now used in many drug discovery applications as well as clinical research and forensic toxicology.

Prior to joining BioTrove in October, 2000 Can was on the faculty at the Massachusetts Institute of Technology where he was an Instructor in the Division of Toxicology and taught undergraduate lecture and laboratory courses along with pursuing independent research.  The division has since been incorporated into the Department of Biological Engineering. 

About TissueNetix, Inc.

TissueNetix is dedicated to developing novel assays that make use of human cells to help eliminate toxic compounds during the drug discovery process.  We are developing a novel microplate format of beating, conducting human cardiomyocytes for the most accurate and efficient drug cardiotoxicity screening.  TissueNetix applies cell engineering to address unmet needs in the drug discovery process, and plans to develop a portfolio of novel tools for preclinical and diagnostic applications.

Press Release
CONTACT: Robert Ellis
CEO & Chairman, TissueNetix, Inc. 
Tel: (510) 557-1155                                                                         June 8, 2012
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Go to top